AUS
NZ
UK
CA
USA
IND
Highlights
- Quarterly reports show mixed results for life sciences companies.
- Next Science shares drop significantly after sales decline.
- Aroa Biosurgery sees strong growth in sales.
As the end of October approaches, many companies in the life sciences sector are releasing their quarterly reports, revealing a range of results. Some companies show growth and progress, while others face challenges.
Next Science (ASX:NXS), a company known for its wound-healing products, reported a decline in product sales, causing its shares to fall by 33%. The company’s total sales amounted to $4.7 million, reflecting a 7% drop compared to the previous year. Sales from its direct channels in the U.S. also decreased by 14%, reaching $3.5 million. Next Science attributes this to its transition from a direct sales model to becoming a durable medical equipment (DME) supplier, which could eventually lead to faster sales and easier reimbursement. Despite the overall drop in sales, the company noted a 44% increase in sales of its newer Xperience product, a surgical irrigation wash designed to prevent infections.
In contrast, Aroa Biosurgery (ASX:ARX), a New Zealand-based company, reported significant growth, with receipts of NZ$19.9 million, up 35% from the previous year. The company’s net cash outflows were halved to NZ$1.2 million. Aroa’s success is largely attributed to its flagship product, Myriad Matrix, a specialized graft used in soft tissue reconstruction and the treatment of complex wounds.
ImpediMed (ASX:IPD), another player in the life sciences sector, faced challenges as well. The company reported a 7% decline in revenue, reaching $2.7 million. ImpediMed’s Sozo devices, which are used to detect lymphedema, saw slower sales due to distributors working through existing inventory. Despite this, the company managed to sell 28 units in the U.S. during the quarter, a slight increase from the previous quarter.
Meanwhile, Elixinol Wellness (ASX:EXL) posted its strongest quarterly performance in four years, with customer receipts reaching $4.1 million, a 77% increase in revenue compared to the previous period. This marks the company’s continued progress in the 'sustainable nutrition' sector, following its shift from cannabis products.
Finally, Proteomics International Laboratories (ASX:PIQ) reported $253,000 in customer receipts as it prepares to launch its predictive diabetes tool, PromarkerD, in 2025.
